Cyclophosphamide‐asparaginase‐vincristine‐prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia

N/ACitations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A remission‐induction regimen for childhood leukemia using cyclophosphamide, asparaginase, vincristine, and prednisone (CAVP) was compared to standard vincristine‐prednisone (VP) induction. The more intensive regimen was associated with a lower complete remission rate (81% vs 93%) and a higher early death rate from infection (15% vs 5%) for acute lymphocytic leukemia. In contrast, complete remission was achieved in 58% of children with acute nonlymphocytic leukemia treated with CAVP compared to 18% for VP. Early death rates were similar (27% vs 25%). These observations corroborate previous studies in childhood nonlymphocytic leukemia showing activity for asparaginase. Preliminary analysis of remission duration and survival for responders shows no advantage for those who survived the more intensive induction. Copyright © 1976 American Cancer Society

Cite

CITATION STYLE

APA

Komp, D. M., George, S. L., Falletta, J., Land, V. J., Starling, K. A., Humphrey, G. B., & Lowman, J. (1976). Cyclophosphamide‐asparaginase‐vincristine‐prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia. Cancer, 37(3), 1243–1247. https://doi.org/10.1002/1097-0142(197603)37:3<1243::AID-CNCR2820370303>3.0.CO;2-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free